SKB571 in recurrent or metastatic head and neck cancer in adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, open-label Phase II trial evaluating the safety, tolerability, and preliminary efficacy of SKB571 in participants with recurrent or metastatic head and neck squamous cell carcinoma. The study also assesses pharmacokinetics and immunogenicity, and includes combination arms with Pembrolizumab, carboplatin, and cisplatin. Eligible adults are 18 to 75 years old with measurable disease and adequate organ function, requiring systemic therapy not curable by local treatment. Key endpoints include objective response rate and safety signals. The trial is conducted at centers in Chengdu and Shanghai, sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 and ≤ 75 years at the time of signing the informed consent form.
* Histologically or cytologically confirmed recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that is not curable by local therapy and not amenable to curative surgery, with the primary tumor located in the oral cavity, oropharynx, hypopharynx, or larynx.
* Subjects with at least one measurable lesion assessed by the investigator according to RECIST v1.1.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 within 7 days before the first dose.
* Participants who have adequate bone marrow, liver, kidney, and coagulation function.
* Male and female participants must agree to use highly effective methods of contraception during the specified period of the study.
* Participants must voluntarily join this study, sign the informed consent form (ICF), and be able to comply with the visits and related procedures specified in the protocol.

Exclusion Criteria:

* History or current metastases to central nervous system.
* Subjects with other malignant tumors within 3 years prior to the first dose.
* Presence of any cardiovascular and cerebrovascular disorders or risk factors.
* Presence of uncontrolled systemic disease.
* Presence of clinically symptomatic or uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
* History of interstitial lung disease (ILD) or non-infectious pneumonitis.
* Presence within 3 months before the first dose of other moderate to severe lung disorders.
* Tumor invasion or compression of surrounding vital organs and major blood vessels.
* Unresolved toxicity from prior anti-tumor therapy.
* Serious infection within 4 weeks before the first dose.
* Presence of active HIV, hepatitis B or hepatitis C or co-infection with HBV and HCV.
* Known active pulmonary tuberculosis.
* Known history of allogeneic organ transplant or hematopoietic stem cell transplant.
* History of allergy to any component of the study drug or severe hypersensitivity to other monoclonal antibodies.
* Participants who have undergone major surgery or had severe trauma within 4 weeks before the first dose, or are expected to require major surgery during the study.
* Participants who have received other investigational drug treatments within 4 weeks before the first dose.
* Prior vaccination with a therapeutic anti-tumor vaccine, or any live vaccine within 4 weeks before the first dose, or planned vaccination with a live vaccine during the study.
* Participants who received systemic corticosteroid therapy with \>10 mg/day of prednisone or other immunosuppressive drugs within 2 weeks before the first dose.
* Received strong inhibitors or strong inducers of cytochrome P450 (CYP3A4) or breast cancer resistance protein (BCRP) inhibitors within 2 weeks prior to the first dose or within 5 half-lives of the known drug (whichever is longer).
* Pregnant or breastfeeding women.
* Known history of psychosis or drug abuse that prevents the participant from cooperating with the study.
* Have local or systemic diseases caused by non-malignant tumors, or diseases or symptoms secondary to tumors, which may lead to higher medical risk and/or uncertainty in survival assessment, or may affect protocol compliance.
* Any condition that, in the investigator's opinion, interferes with the evaluation of the investigational product, participant safety, or interpretation of study results, or any other condition that the investigator deems unsuitable for participation in this study.

Where it's running

• West China Hospital, Sichuan University
  Chengdu, China Recruiting
• Shanghai Oriental Hospital
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Xin Li
• Email: lixin@kelun.com
• Phone: +86 10 58302512

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TMV vaccine alone or with toripalimab for recurrent head and neck cancer

  This study tests a personalized TMV vaccine, alone and with toripalimab, in adults whose head and neck cancer has returned and is planning salvage surgery.

  Recruiting Phase 1 Metaclipse Therapeutics Corporation · Houston, Texas · NCT07898124

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• TS-104: a first-in-human, dose-escalation study for advanced solid tumors

  This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.

  Recruiting at 3 sites Phase 1 TwoStep Therapeutics, Inc. · Maumee, Ohio and 2 other locations · NCT07814248

• Intratumoral fluorescent nivolumab before surgery in head and neck cancer

  This study tests injecting fluorescently labeled nivolumab directly into head and neck tumors to see if it is safe and whether it reaches nearby lymph nodes before surgical removal.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07741565

• Proton versus photon treatment for squamous cell cancers of the head and neck

  This trial will test whether proton radiation or standard photon radiation leads to less long-term dry mouth, swallowing problems, pain, and speech issues in people aged 40 and older with squamous cell cancers of the oral cavity, oropharynx, hypopharynx, or larynx treated with curative radiotherapy.

  Recruiting Phase 3 Oslo University Hospital · Bergen and 3 other locations · NCT07580300

• EPI-326 for EGFR-mutant non-small cell lung cancer and head and neck squamous cell carcinoma

  This phase 1 trial will try EPI-326, a new drug, in people with EGFR-mutant non‑small cell lung cancer or advanced head and neck squamous cell carcinoma to find safe doses, study how the body handles it, and look for early signs it shrinks tumors.

  Recruiting at 8 sites Phase 1 EpiBiologics · Los Angeles, California and 7 other locations · NCT07462377

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.